Benefits
Supports lumbar spine bone density
In a 12-month randomized trial in postmenopausal women, FORTIBONE® at 5 g/day was shown to support increases in lumbar spine bone mineral density compared with placebo, suggesting a role in maintaining skeletal strength during midlife and beyond.
Supports femoral neck bone density
FORTIBONE® supplementation has been shown to support increases in femoral neck bone mineral density in postmenopausal women with reduced BMD, a clinically meaningful site given fall- and hip-related concerns in aging adults.
Promotes a favorable bone remodeling balance
Markers of bone formation increased and markers of bone breakdown showed favorable trends in adults using FORTIBONE®, consistent with a shift in bone remodeling balance that helps maintain bone matrix over time.
Easy daily addition for women's bone routine
FORTIBONE® dissolves easily in water, coffee, or smoothies and is essentially tasteless, making it a convenient companion to calcium and vitamin D regimens for women focused on midlife and postmenopausal bone health.
Well-tolerated in long-term clinical use
FORTIBONE® showed a favorable tolerability profile across 12 months of daily 5 g use in postmenopausal women, supporting its suitability for long-term bone health programs.
Mechanism of action
Osteoblast stimulation by collagen peptides
Specific bioactive peptides in FORTIBONE® are absorbed and may reach bone tissue, where they can signal osteoblasts to increase synthesis of type I collagen, the main organic component of the bone matrix on which mineralization occurs.
Substrate supply for bone matrix
Collagen peptides provide glycine, proline, and hydroxyproline in the high concentrations needed for de novo synthesis of bone collagen, complementing minerals such as calcium and phosphate that build the mineral phase.
Optimized peptide profile
GELITA's proprietary enzymatic hydrolysis yields a defined peptide spectrum (~3-5 kDa) intended to maximize delivery of bioactive fragments relevant to bone cells, differentiating FORTIBONE® from non-specific collagen hydrolysates.
Modulation of bone turnover markers
Clinical data show that FORTIBONE® can favorably influence serum markers of bone formation and resorption, consistent with a net shift toward bone matrix accrual in postmenopausal women with low BMD.
Clinical trials
Randomized, double-blind, placebo-controlled trial; 12 months; 5 g/day FORTIBONE®.
102 postmenopausal women with reduced (primary) BMD at lumbar spine or femoral neck.
Daily FORTIBONE® significantly increased lumbar spine and femoral neck BMD compared with placebo over 12 months, with favorable changes in bone formation markers, supporting its use as a bone health adjunct in postmenopausal women.
Controlled trial of calcium and vitamin D with or without collagen peptides; bone turnover markers assessed.
Postmenopausal women with osteopenia.
Addition of specific collagen peptides to calcium and vitamin D was associated with favorable changes in bone turnover markers compared with calcium and vitamin D alone, supporting a potential adjunctive role of collagen peptides in osteopenic women.